Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

Autor: Alexandra Calmy, Tamara Tovar Sanchez, Charles Kouanfack, Mireille Mpoudi-Etame, Sandrine Leroy, Ségolène Perrineau, Martial Lantche Wandji, Darius Tetsa Tata, Pierette Omgba Bassega, Thérèse Abong Bwenda, Marie Varloteaux, Marcel Tongo, Eitel Mpoudi-Ngolé, Alice Montoyo, Noémie Mercier, Vincent LeMoing, Martine Peeters, Jacques Reynes, Eric Delaporte, A Calmy, T Tovar Sanchez, C Kouanfack, M Mpoudi-Etame, S Leroy, S Perrineau, M Lantche-Wandji, D Tetsa-Tata, P Omgba-Bassega, T Abong-Bwenda, M Varloteaux, M Tongo, E Mpoudi-Ngolé, A Montoyo, N Mercier, V LeMoing, M Peeters, J Reynes, E Delaporte, A Ayouba, A Agholeng, C Butel, A Cournil, S Eymard-Duvernay, B Granouillac, S Izard, A Lacroix, L Serrano, N Vidal, PJ Fouda, R Mougnoutou, J Olinga, V Omgba, SC Tchokonte-Ngandé, B Ymele, CD Epoupa-Mpacko, M Fotso, R Moukoko, T Nké, A Akamba, S Lekelem, SB Tongo-Fotack, S Ngono, M Tanga, E Ebong, G Edoul-Mbesse, L Ciaffi, S Koulla-Shiro, G Manirakiza, ED Mimbé, S Boyer, M Bousmah, G Maradan, ML Nishimwe, B Spire, MP Lê, G Peytavin, A Diallo, I Fournier, C Rekacewicz, C Perez Casas

Publikováno v: The Lancet HIV
The Lancet HIV, 2020, 7 (10), pp.e677-e687. ⟨10.1016/S2352-3018(20)30238-1⟩

International audience; Background: Updated WHO guidelines recommend a dolutegravir-based regimen as the preferred first-line treatment for HIV infection and low-dose efavirenz (400 mg) as an alternative. We aimed to report the non-inferior efficacy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e04f3e8044bec57d70cb397c548401b0
https://hal.umontpellier.fr/hal-03337700

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial

Autor: Laura Ciaffi, Sinata Koulla-Shiro, Adrien Bruno Sawadogo, Cheik Tidiane Ndour, Sabrina Eymard-Duvernay, Pretty Rosereine Mbouyap, Liliane Ayangma, Jacques Zoungrana, Ndeye Fatou Ngom Gueye, Mohamadou Diallo, Suzanne Izard, Guillaume Bado, Coumba Toure Kane, Avelin Fobang Aghokeng, Martine Peeters, Pierre Marie Girard, Vincent Le Moing, Jacques Reynes, Eric Delaporte, J Reynes, E Delaporte, S Koulla-Shiro, CT Ndour, AB Sawadogo, M Seidy, V Le Moing, A Calmy, L Ciaffi, NF Ngom Gueye, PM Girard, S Eholie, JB Guiard-Schmid, ML Chaix, C Kouanfack, I Tita, B Bazin, P Garcia, S Izard, S Eymard-Duvernay, M Peeters, L Serrano, A Cournil, PR Mbouyap, R Toby, N Manga, L Ayangma, M Mpoudi, Ngole J Zoungrana, M Diallo, AF Aghokeng, E Guichet, O Bell, H Abessolo Abessolo, MR Djoubgang, G Manirakiza, G Lamarre, T Mbarga, S Epanda, A Bikie, T Nke, N Massaha, E Nke, D Bikobo, J Olinga, O Elat, A Diop, B Diouf, N Bara, MB Koita Fall, C Toure Kane, FB Seck, S Ba, P Njantou, A Ndyaye, P Fao, R Traore, Y Sanou, G Bado, M Coulibaly, E Some, J Some, A Kambou, A Tapsoba, D Sombie, S Sanou, B Traore, P Flandre, C Michon, J Drabo, F Simon

Publikováno v: Lancet HIV
Lancet HIV, 2017, 4 (9), pp.e384--e392. ⟨10.1016/S2352-3018(17)30069-3⟩
Lancet HIV, Elsevier, 2017, 4 (9), pp.e384--e392. ⟨10.1016/S2352-3018(17)30069-3⟩

Despite satisfactory efficacy of WHO-recommended second-line antiretroviral treatment for patients with HIV in low-income countries, the need for simplified, low-cost, and less-toxic maintenance strategies remains high. We compared boosted protease i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e134a5a3ec01e9f053cb6a49d0a556f0
https://hal.science/hal-01761365

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.